Clinical trial to find new treatment for visceral leishmaniasis begins in eastern Africa

Addis Ababa – 13 April 2018
Study launched as part of new Afri-KA-DIA Consortium will also assess diagnostic tools
A new study to find a safer, efficacious and more patient-friendly treatment and improved diagnostic tools for people living with visceral leishmaniasis (VL) has begun in eastern Africa, within the new Afri-KA-DIA consortium with funding from The European & Developing Countries Clinical Trials Partnership (EDCTP). The large-scale Phase III clinical trial seeks to assess the efficacy and safety of a combination of miltefosine and paromomycin in treating VL in eastern Africa.

NITD Workshop

4-5 June 2018
Emeryville, USA

Isabela Ribero, Scientific Dynamic Portfolio Leader, DNDi – clinical overview on Chagas disease and discussion on adjunct therapies
Charles Mowbray, Discovery Director, DNDi – discussion on Chagas disease and leishmaniasis global pre-clinical portfolio

Takeda Pharmaceutical and DNDi collaborate to progress a potential new drug for visceral leishmaniasis through the R&D pipeline

Osaka, Japan and Geneva, Switzerland – 5 April 2018
Efforts funded by the Global Health Innovative Technology Fund for pre-clinical and phase I clinical studies
Takeda Pharmaceutical Co., Ltd. and DNDtoday announced that they have signed an agreement to collaborate in conducting preclinical and phase I clinical studies on drug candidate compounds that had been discovered among the aminopyrazole compound class, aimed at developing an innovative drug for the treatment of visceral leishmaniasis (VL).
[Japanese]

MSF Scientific Days 2018

24-25 May 2018
London, UK
Olawale Salami, Paediatric HIV Clinical Project Manager DNDi Africa – presentation of the LIVING study on treatment for paediatric HIV
Leishmaniasis Team, DNDi – presentation on PKDL in the Indian subcontinent
Jorge Alvar, Senior Leishmaniasis Advisor, DNDi – presentation on HIV-VL in East Africa

DNDi welcomes Astellas to the NTD Drug Discovery Booster

The Japanese pharmaceutical company Astellas Pharma Inc. is the eighth pharmaceutical company to join the Neglected Tropical Diseases Drug Discovery Booster, a global consortium launched in 2015 by DNDi to speed up the process and cut the cost of finding new treatments for leishmaniasis and Chagas disease.

DNDi, GlaxoSmithKline, and University of Dundee to identify drug candidates to treat leishmaniasis and Chagas disease

Geneva / Brentford / Dundee – 27 March 2018
The not-for-profit research and development organization Drugs for Neglected Diseases initiative (DNDi) will collaborate with GlaxoSmithKline (GSK), and the University of Dundee Drug Discovery Unit (DDU), in a bid to discover new pre-clinical drug candidates targeting two parasitic neglected tropical diseases (NTDs), leishmaniasis and Chagas disease.

Geneva Health Forum

7th Edition: Precision Global Health in the Digital Age

10-12 April 2018
Geneva, Switzerland
Bernard Pécoul, Executive Director – plenary talk on emerging infectious diseases crisis
Digas Ngolo, Investigator Coordinator, DNDi Africa – parallel session on ehealth

Harmonized clinical trial methodologies for localized cutaneous leishmaniasis and potential for extensive network with capacities for clinical evaluation

by Olliaro P, Boni M, Carvalho EM, Chebli H, Cisse M, Diro E, Fernandes Cota G, Erber AC, Gadisa E, Handjani F, Khamesipour A, Llanos-Cuentas A, López Carvajal L, Grout L, Lmimouni BE, Mokni M, Nahzat MS, Ben Salah A, Ozbel Y, Pascale JM, Rizzo Molina N, Rode J, Romero G, Ruiz-Postigo JA, Gore Saravia N, Soto J, Uzun S, Mashayekhi V, Vélez ID, Vogt F, Zerpa O, Arana B.

PLoS Neglected Tropical Diseases, January 2018